Dana–Farber Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2022

  1. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

    Journal for immunotherapy of cancer, Vol. 10, Núm. 5

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma

    Clinical Cancer Research